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ABSTRACT 
Background: In South Africa, hepatitis B virus (HBV) infection remains a major cause of 
morbidity and mortality, however, little is known about the prevalence and distribution of HBV 
in some regions and populations.  
Methods: This secondary analysis is based on 9791 participants (15-49 years old) enrolled in 
the HIV incidence Provincial Surveillance System (HIPSS); a population-based household 
study undertaken from June 2014 to June 2015 in the Vulindlela (rural) and Greater Edendale 
(periurban) areas of the uMgungundlovu district, KwaZulu-Natal (KZN), South Africa. 
Interviewer administered questionnaires were completed to obtain demographic, psycho-
social, behavioural and clinical information. Peripheral blood samples were collected and sera 
were tested for hepatitis B surface antigen (HBsAg) and all samples testing positive were 
further tested for hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe). The 
estimated weighted seroprevalence of HBV markers was calculated and the association of 
HBsAg with sociodemographic and behavioural factors measured.  
Results: The overall HBsAg prevalence was 4.0% (95% confidence interval (CI) 3.4-4.5); 
4.8% (95% CI 3.8- 5.8) in men and 3.2% (95% CI 2.5-3.9) in women, P=0.01. Among HBsAg 
positive participants, 35.2% (95% CI 29.2-41.2) were HBeAg positive and 66.3% (95% CI 
60.1-72.4) were anti-HBe positive. Among men 15-19 years old HBeAg seroprevalence was 
92.2% (95% CI 75.8-100) compared to 4.4% (95% CI 0-13.7) in women in the same age group; 
P <0.01. HBsAg prevalence was 6.4% (95% CI 5.3-7.5) among HIV positive participants 
compared to 2.6% (95% CI 1.9-3.2) among HIV negative participants, (P<0.01) and was higher 
among HIV positive men 8.7% (95% CI 6.3-11.2) compared to HIV positive women 5.0% 
(95% CI 3.8-6.2), P<0.01. 
Conclusion: HBV infection, particularly among HIV positive men remains an important public 
health problem in rural and periurban communities in KwaZulu-Natal, South Africa. The 
prevalence of HBsAg and HBeAg highlight the importance of surveillance and an important 
missed opportunity for the scale up of programmes to achieve the goal of controlling HBV for 
public health benefit. 

























Samsunder – Seroprevalence of HBV 
2 
1.0 CHAPTER 1: INTRODUCTION 
1.1 Overview  
Almost eight percent of the 257 million people globally infected with Hepatitis B virus (HBV) 
reside in sub-Saharan Africa, with over 80 000 new infections occurring each year. HBV is a 
common cause of viral hepatitis, which affects the liver resulting in acute or chronic liver 
disease and complications of cirrhosis and hepatocellular carcinoma contributing to high rates 
of morbidity and mortality (WHO, 2017). 
In 1995, the South African Department of Health introduced the HBV vaccine into the 
Expanded Programme on Immunisation at 6, 10 and 14 weeks of age. However, there was no 
catch-up immunization programme for older children and adults to ensure complete vaccine 
coverage (Tsebe et al., 2001). Despite the widespread implementation of HBV immunization, 
recent data indicate that HBV prevalence ranges between 0.0% and 13.2% in infants (Vardas 
et al., 1999, Tsebe et al., 2001, Mphahlele et al., 2002, Mdlalose et al., 2016), 7.0% and 10.0% 
in adults (Burnett et al., 2012, Matthews et al., 2015), and 0.0% and 5.3% in pregnant women 
(Thumbiran et al., 2014). Compared to any other racial or ethnic groups, black South Africans 
represent a population most affected by HBV infection, with the prevalence between 5.0% and 
16.0% in rural males, 8.0% to 9.0% in urban males, 4.0% to 12.0% in rural females and 3.0% 
to 4.0% in urban females (Vos et al., 1980, Kew et al., 1976, Prozesky et al., 1983, Kew et al., 
1987, Abdool Karim et al., 1988, Dusheiko et al., 1989).  
 
South Africa contributes a disproportionate 70% of all the world’s human immunodeficiency 
virus (HIV) infection, with over seven million people living with HIV in 2017 (UNAIDS, 
2017). Similar to heterosexual transmission of HIV-1, HBV infection through the genital 
mucosa in women is a potential route of infection (Shattock and Moore, 2003, Abdool Karim 
et al., 2010, UNAIDS, 2017). Most HBV-HIV co-infected individuals may have acquired HBV 
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horizontally in childhood and HIV sexually in adulthood. Therefore, it is not unexpected that 
co-infection with HBV and HIV is common (Soriano et al., 2007). Unlike HIV, routine HBV 
screening is not offered in South Africa, yet local studies have reported HBV and HIV 
coinfections rates between 0.4% and 22.9% (Firnhaber et al., 2008, Firnhaber, 2008, 
Lukhwareni et al., 2009, Boyles and Cohen, 2011, Mayaphi et al., 2012, Bell et al., 2012, Ayuk 
et al., 2013, Thumbiran et al., 2014, Matthews et al., 2015, Mdlalose et al., 2016, King, 2016). 
In addition, studies from South African have shown variability in HBsAg positivity rates of 
19.8% in an HIV care and treatment cohort (Hoffmann et al., 2008),  4.8% (Firnhaber et al., 
2008) and 6.5% (Mayaphi et al., 2012) in urban cohorts, 22.9% in a periurban (Lukhwareni et 
al., 2009) and 7.1% (Boyles and Cohen, 2011) in rural settings. Consequently, HBV is a 
growing cause of liver cirrhosis, end-stage liver disease, and death among people living with 
HIV. HIV treatment guidelines by the Southern African HIV Clinicians Society recommend 
that all HIV infected patients attending the antiretroviral therapy (ART) clinics to start 
treatment must be screened for HBsAg (Meintjes et al., 2014). There are several anti-HIV 
agents approved for treating HBV, two of them being lamivudine (3TC) and tenofovir 
disoproxil fumarate (TDF) (Keeffe and Marcellin, 2007, Palumbo, 2008, United States Food 
and Drug Administration., 2017).Our anti-retroviral regimen at present is a fixed drug 
combination of Efavirenz/ Emtricitabine/ Tenofovir and is highly effective against both HBV 
and HIV. HIV-HBV co-infected individuals are by default effectively treated for both 
infections with the present antiretroviral regimen. Due to lack of screening in South Africa, 
HBV mono -infected individuals are usually not diagnosed and are often only identified 
when they present with complications of chronic liver disease. Routine screening, 
immunization and treatment for HBV and HIV may assist to achieve the World Health 
Organisation (WHO) goal of eliminating viral hepatitis as a major public health threat by year 
2030. 
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Given that the WHO strategy is to eliminate HBV as a public health threat by the year 2030, 
(World Health Organisation., 2017, World Health Organisation., 2016) it is important to 
establish what the seroprevalence is through surveillance. The purpose of this study was to 
assess the HBV seroprevalence as part of a household survey in rural and periurban areas in 
KwaZulu-Natal, South Africa.  
1.2 Aims and Objectives 
1.2.1 Aim of the study 
• To determine the prevalence and distribution of HBV infection markers in a population-
based sample of men and women 15-49 years old in Vulindlela (rural) and Greater 
Edendale (periurban) KwaZulu-Natal, South Africa. 
1.2.2 Objectives: 
• To determine the prevalence of markers of active HBV infection (serum HBV surface 
antigen; HBsAg positive), active replication of virus (serum HBV envelope antigen; 
HBeAg positive), and recovery from infection (serum anti-HBe (HBeAb) positive) in 
the population-based sample of men and women 15-49 years old.  
• To determine the association of prevalence and distribution of HBV by sex and age. 
• To determine the prevalence and distribution of HBV-HIV co-infection. 
1.3 Hypothesis: 
We hypothesised that the prevalence of HBV is high in this rural and periurban communities 
and the imperative for improved surveillance to guide the scale up of HBV control 
programmes.  
1.4 Significance of the study: 
This study will inform current clinical screening recommendations and enhance our 
understanding of the distribution of HBV and HBV-HIV co-infection in the study sample.  
























Samsunder – Seroprevalence of HBV 
6 
2.0 CHAPTER 2: LITERATURE REVIEW 
2.1 Composition of hepatitis B virus structure 
Hepatitis B infection is caused by the hepatitis B virus, a small DNA virus that belongs to the 
Hepadnaviridae family (Ott et al., 2012). The virus has features similar to retroviruses and 
humans are its only known host (Centres for Disease Control and Prevention., 2017). The 
complete infectious virion known as Dane particle, has a 42 nm (diameter) double shelled 
structure made up of surface proteins and lipids from the hepatocyte membrane, outer envelope 
of viral S proteins, the outer protein nucleocapsid (27nm) and an inner protein core (27nm), 
(Figure 2.1), (Dane et al., 1970). The outer protein nucleocapsid structure contains the hepatitis 
B surface antigen (HBsAg) made up of spheres and filaments (Gavilanes et al., 1982). The 
inner protein core contains the hepatitis B core antigen (HBcAg), a partially double stranded 
DNA molecule and a soluble non- nucleocapsid hepatitis B e antigen (HBeAg). The complete 
HBV genome is about 3.2 kilobase (kb) pairs sequence length (Gerlich and Robinson, 1980, 
Gitlin, 1997).  
 
Although similar to HIV reverse transcriptase (RT) enzyme, the trademark HBV replication is 
protein-primed reverse transcription, the mechanism is distinct from that of HIV RT replication 
(Liang, 2009). HBV establish infection through attaching to the host cell membrane using the 
pre-S domain of the surface protein. Once the viral genome is inside the cell, the single stranded 
gap region in the viral genome is repaired and circularized by the pol protein of the virus to 
serve as a template for reverse transcription of several species of genomic RNAs (Kang et al., 
2006, Kock and Schlicht, 1993). Replication of HBV starts with the encapsidation of the 
genome, followed by the reverse transcription of the pregenome RNA (pgRNA) to minus 
strand DNA, subsequently positive strand synthesis and several steps of strand transfer. After 
the replication steps, the immature viral particles migrate to the endoplasmic reticulum to be 
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assembled into mature viruses, which are the secreted into the blood stream (Will et al., 1987, 
Pollack and Ganem, 1993). Once the HBV infection has been established, the body produces 
antibodies to its antigens. The antibodies involved are Hepatitis B surface antibody (anti-
HBs/HBsAb), Hepatitis B core antibody (anti-HBc/HBcAb) and Hepatitis B e antibody (anti-
HBe/HBeAb). Multiple number of viral antigens and their corresponding antibodies can be 
detected in serum samples during or after HBV infection but  the isolated measure of HBsAg 
in serum may not always indicate infectivity or viral replication since HBsAg can circulate in 
blood free of viral particles and is not infectious (Gitlin, 1997). HBV DNA level s determine 
the degree of replication as HBV-infected individuals can be HBsAg positive, HBeAg 
negative and actively replicating in the setting of precore/basal core promotor mutations. 
 
Figure 2.1. Hepatitis B virion 42nm in diameter and an inner core 27nm in diameter which 
contains the partially double stranded DNA genome (Figure adapted from Jagtar Singh, 
Department of Biotechnology, Panjab University, Chandigarh, India. 
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2.2 Natural history of Hepatitis and distribution of genotypes 
Hepatitis or liver inflammation is the infection of the liver tissue caused by the hepatitis virus 
(WHO, 2016). Excessive alcohol intake, some medications or medical conditions, toxic 
substances, parasitic infections and autoimmune conditions are some of the factors also known 
to  cause hepatitis (WHO, 2016). The condition is often acute, self-limiting and short lived but 
may progress as well. In some instances, the condition may persist and result in chronic 
hepatitis that can cause scarring of the liver, liver failure or liver cancer. Some individuals 
experiencing this condition may have no symptoms in early stages while others may present 
with yellow discolouration of the skin and eyes (jaundice), passing of dark urine, vomiting, 
nausea, loss of appetite, fatigue and abdominal pain (WHO, 2016).  
 
There are 5 different types of hepatitis, namely A, B, C, D, and E. Hepatitis A and E can be 
acquired by the intake of contaminated food or water while hepatitis B can be contracted 
through contact with open sores, wounds, blood and other bodily fluids of an infected person, 
sharing of needles by injectable drug users, transfusion of infected blood products, or from 
mother to baby at birth (NIAID, 2016). There are nine key genotypes of hepatitis B (named A 
to I), which display a unique pattern of geographical distribution worldwide (Figure 2.2.). 
Hepatitis B genotypes A to H have long been accepted as individual genotypes while less 
characterised hepatitis I has recently been described (Kramvis et al., 2005, Kurbanov et al., 
2008, Tran et al., 2008). In Africa, hepatitis A, D and E are the most common genotypes 
observed. Hepatitis A is highly prevalent in Southern and Eastern Africa while hepatitis B and 
C are mostly concentrated in Asia (Kramvis et al., 2005, Kramvis and Kew, 2007). Hepatitis 
A, D and G are associated with frequent injection drug use and blood transfusion, while B and 
C are linked to vertical transmission from mother to child, sexual intercourse, blood transfusion 
and sharing of needles (Krekulova et al., 2003, Liu and Kao, 2013, Komatsu et al., 2015, 
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NIAID, 2016). All hepatitis genotypes respond to treatment with reverse transcriptase 
inhibitors, and interferon alpha, but Hepatitis A, and B can be preventable by effective 
vaccines. Prevention of Hepatitis B by HBV vaccination prevents Hepatitis D acquisition 
(WHO, 2016).  
 
Figure 2.2. Geographical distribution of hepatitis genotypes worldwide. Pie chart and colour 
represent proportion of the genotype distribution by country. (Figure adapted from (Velkov et 
al., 2018). 
 
2.3 Acute and chronic HBV infection 
HBV infection is a self-limiting disease that can lead to a wide spectrum of liver disease which 
can clear within 6 months of acquisition. If acquired in adulthood and the individual is 
immunocompetent, <5% would develop chronic infection. However, in vertical transmission, 
70-90% would develop chronic infection and 30-50% if acquired during childhood. HBV 
acquisition perinatally or in early childhood, which is common occurrence in South Africa is 
usually asymptomatic. If the infection is acquired in adolescents or during adulthood, an 
incubation period ranges from of 45 to 150 days (Gitlin, 1997), followed by evidence of HBV 
DNA and HBsAg in the serum. The serum of an infected patient would normally have increased 
levels of liver enzyme such as aspartate aminotransferase (AST) and alanine aminotransferase 
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(ALT) that are released during the episode of inflammation in the liver. During this time, 
infected individuals may show varied symptoms such as jaundice that’s accompanied by fever, 
tiredness, nausea, vomiting and rash (Previsani, 2002). This infection may persist for a week 
or two, thereafter the patient recovers with HBsAg clearance from circulation but HBV DNA 
still detectable (Liang, 2009). During this period, antibodies to HBsAg, anti-HBs (HBsAb) can 
be measured serve as an indication of immunity to HBV infection (Shepard et al., 2006), 
(Figure 2.3, a). 
 
If HBsAg positivity persists for more than 6 months the patient could be regarded as a 
chronically infected with HBV (Levy and Grant, 2006). In chronically HBV infected patients, 
HBsAg and HBeAg can be detected with high levels of HBV DNA (McMahon, 2009). Chronic 
HBV infection is progressive and has multiple phases that include immune tolerant phase, 
immune clearance phase, immune control phase, immune escape phase and inactive carrier 
phase (Figure 2.3, b). During the immune tolerant phase, the virus cannot be cleared by the 
host immunity and persist with high levels of viral load, high levels of HBeAg and HBsAg. 
However, ALT levels are normal with little or no symptoms and little evidence of impact on 
the liver (Merican et al., 2000). This phase is followed by the immune clearance phase, in which 
HBeAg clearance occurs and HBV DNA levels decrease but ALT levels increase with evidence 
of anti-HBe (HBeAb) antibodies. This phase can last a few months to years (Gitlin, 1997, Pan 
and Zhang, 2005). The following phase is the inactive HBsAg carrier phase (or the non-
replicative).  
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Figure 2.3. The clinical course and serological profiles of a) acute and b) chronic hepatitis B 
(Liang, 2009) 
 
phase) characterized by the loss of HBeAg and the presence of anti-HBe (HBeAb), persistently 
low levels of HBV DNA titers and normal ALT levels. In this phase, there is very little or no 
injury to the liver and can last for years or for life (Gitlin, 1997, Pan and Zhang, 2005, 
McMahon, 2009, Liang, 2009). In some cases, the patient clear HBsAg but later has 
reactivation due to immunosuppression of the patient with reversion to the HBeAg-positive 
phase or emergence of pre-core mutant strains of HBV which are unable to produce HBeAg 
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(Spearman et al., 2013). This phase is called the immune escape phase, with evidence of anti-
HBs (HBsAb) and anti- HBc (HBcAb) but still has detectable HBV DNA with no liver damage 
observed (Spearman et al., 2013). 
 
2.5 Diagnosis and serology of hepatitis B virus infections 
The diagnosis of HBV infection is established on a collection of clinical, biochemical, 
histological, and serologic findings. At the onset of infection, HBsAg is produced in the liver 
and released into the blood and detection of this antigen is evidence of infection and can be 
detected using serological tests (Krajden et al., 2005). Table 2.1. shows HBV serological and 
viral markers used to establish HBV infection and staging of infection. These include HBsAg, 
HBeAg, anti-HBc (Immunoglobulin M -IgM), anti-HBc (IgG), anti-HBe, anti-HBc (IgG) and 
anti-HBs, anti- HBc (IgG) and HBsAg,  anti-HBc (IgG) and/or anti-HBs and HBV DNA (PCR) 
(Krugman et al., 1979, Will et al., 1987). During acute infection, presence of HBV DNA is 
followed by HBsAg and HBeAg as first viral markers present in serum within 1 to 2 weeks or 
as late as 11 to 12 weeks after infection. The presence of HBeAg in the blood is an indication 
of high levels of HBV replication and infectivity while persistence of HBsAg is a marker of 
chronicity.  
  
The viral markers can be accompanied by increased ALT, AST and jaundice (Krugman et al., 
1979, Will et al., 1987). HBeAg is the first marker that is cleared at the peak of clinical illness 
while HBsAg and HBV DNA usually continue to be present in the serum until cleared with 
recovery. Clearance of HBeAg is usually accompanied by a rise in anti-HBe (HBeAb), a 
common serological antibody during acute hepatitis B. Although anti-HBe appears during the 
acute phase, it is not the first antibody during this stage (Tabor et al., 1981). IgM is the first 
antibody to appear during the acute stage and its appearance is triggered by the appearance of 
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anti-HBc (HBcAb), but this antibody decline as levels of IgG anti-HBc rise. The HBeAg 
negative reactivation phase is HBsAg positive, anti-HBs negative, anti-HBc positive, HBeAg 
negative and anti-HBe positive with HBV DNA levels >2000 IU/ ml. Anti-HBs tend to arise 
and persist during recovery or after clearance of HBsAg. Some individuals do not develop 
detectable levels of anti-HBs, but develop anti-HBc, a marker of previous infection. 
Consequently, in South Africa, anti-HBc is the most reliable and widely used marker for 
assessing previous infection and response to HBV vaccine (Tabor et al., 1981). 
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Table 2.1. The serological tests used to establish hepatitis B infection and staging of infection 
(Liang, 2009) 
Test Interpretation 
HBsAg HBV infection, both acute and chronic 
HBeAg 
High-level HBV replication and infectivity; marker for 
infectivity 
HBV DNA 
Level of HBV replication; primary virologic marker for 
treatment response 
Anti-HBc (IgM) 
Acute HBV infection; could be seen in flare of chronic 
hepatitis B 
Anti-HBc (IgG) 
Is the best marker of previous HBV exposure and 
is always positive in chronic HBV infection. 
Anti-HBe 
Indicates the individual has cleared HBeAg; marker for 
treatment response. 
Anti-HBc (IgG) and anti-
HBs 
Past HBV infection; could lose anti-HBs 
Anti- HBc (IgG) and 
HBsAg 
Chronis HBV infection 
Anti-HBc (IgG) and/or 
anti-HBs and HBV DNA 
(PCR) 
Latent or occult HBV infection 
 
2.6 Epidemiology of HBV with emphasis on Africa 
Almost two billion people alive today have been infected with HBV globally, with 257 million 
infected cases and 887 000 deaths reported in 2015 (WHO, 2017). Eighteen percent of the 
global HBV infections are found in Africa, with the sub-Saharan Africa region accounting for 
8% of the burden of disease. Zimbabwe has the highest prevalence (25%), followed by Mali 
(15.5%), Burkina Faso (14.5%), Ghana and Senegal (13.8%), Nigeria (13.6%), Mauritania 
(10.9%), Cameroon (10.1%), Gabon (9.5%) and Zambia (6.5%).  
In South Africa, local epidemiological studies show varying prevalence of HBV infection 
according to the region and population under investigation. Several studies have shown that 
HBV infection in South Africa is more common in rural than in urban areas (Vos, Rose, & 
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Marimuthu, 1980; Di Bisceglie et al., 1986; WHO, 2008) and black South Africans represent 
a population most affected by HBV infection. Studies conducted prior to widespread 
immunization programmes in 1995 showed that the HBV prevalence was 10%, 18.5% and 
25.1% among black children aged 6-14 years old from urban areas, rural areas and residential 
care facilities respectively (Abdool Karim et al., 1988). In addition, the prevalence was between 
5.0% and 16.0% in rural males, 8.0% to 9.0% in urban males, 4.0% and 12.0% in rural females 
and 3.0% and 4.0% in urban females (Kew et al., 1976, Vos et al., 1980, Prozesky et al., 1983, 
Kew et al., 1987, Abdool Karim et al., 1988, Dusheiko et al., 1989). Although HBV infection 
occurs predominantly in the black population, a small community of Chinese residents of South 
Africa are also disproportionately affected. One study by Song and colleagues (1988) 
demonstrated that the HBV carrier rate among the South African Chinese population was 5.3%. 
Whites and Indians had a HBV carrier rate of 0.2% and an exposure rate of 5.0%, whilst whites 
with European origin had a carrier rate of 0.4-3.0% and a total exposure rate of 18.0-25.0%. 
 
Despite the widespread implementation of HBV immunization, recent data indicate that HBV 
prevalence ranges between 0.5% and 13.2% in infants (Vardas et al., 1999, Tsebe et al., 2001, 
Mphahlele et al., 2002, Mdlalose et al., 2016), 7.0% and 10.0% in adults  (Burnett et al., 2012, 
Matthews et al., 2015), and 0.0% and 5.3% in pregnant women (Thumbiran et al., 2014). In 
addition, recent studies showed a high prevalence of HBV infection (between 5.3% and 10.0%) 
in KwaZulu Natal compare to other South African provinces (Thumbiran et al., 2014, 
Matthews et al., 2015, Mdlalose et al., 2016). This is no surprise considering that the province 
of KwaZulu-Natal is the epicentre of HIV infection worldwide (Kharsany et al., 2018) and 
HBV share a common transmission route with HIV. Table 2.2 highlights the geographic, age 
and sex variation with South Africa.  
Samsunder – Seroprevalence of HBV 
16 
Table 2.2: Comparison of studies discussed in the literature review 
Author/Citation Population Location  Sample size (n) HBV prevalence (%) 
(Burnett et al., 2005) General population Rural population in South Africa unknown 10.0% 
(Kew, 1996b) In hospital patients Johannesburg 231 8.6% 
(Kew et al., 1976) adults Gauteng 1050 
0.2% White Diabetics  
4.6% Black diabetics 
1.4% White Hospital patients 
4.3% Black hospital patients 
(Dibisceglie et al., 1986) 
Urban-children 3-19 year 
old 
Soweto 2364 1.0% 
(Kew et al., 1987) Urban and  rural population Soweto 1234 1.3% urban; 4.0% rural 
(Tsebe et al., 2001) Under 5 year olds Northern province 598 13.2% 
(Prozesky et al., 1983) Rural adult 
Mpumalanga (formally 
Kangwane)  
1495 14.6% in men; 4.6% in women 
(Mphahlele et al., 2002) Infants Limpopo 186 0.0% 
(Jooste et al., 2016) <17 year olds Kimberly 625 0.8% 
(Vardas et al., 1999)  0-6 year old. Eastern Cape 2299 10.4% 
(Chotun et al., 2015) infants Western Cape 1000 0.4% 
(Vos et al., 1980) Black adults Durban and Transkei unknown 7.4% Durban; 15.5% Transkei 
(Thumbiran et al., 2014) Pregnant women KwaZulu Natal 570 5.3% 
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(Mdlalose et al., 2016) infants KwaZulu Natal 322 
10.0% overall (13.0% in HIV + 
and 7.5% in HIV-) 
(Abdool Karim et al., 1989) Adult men and women Northern KwaZulu Natal 441 5.0% 
(Abdool Karim et al., 1988) School children Mseleni 238 18.4% 
(Dusheiko et al., 1989) Mine workers 
18 geographic locations in South 
Africa 
29312 9.9% 
(Matthews et al., 2015) Adult women South Africa 1022 9.7% 
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2.6.1 HBV-HIV co-infection  
In Europe, sexual transmission among men who have sex with men is the most common mode 
of acquisition of HIV while heterosexual contact and injecting drug use were the main modes 
of transmission in eastern Europe. In Southern Africa the main mode of HIV acquisitions is via 
mother to child transmission at birth or via heterosexual transmission among adolescents and 
adults. Due to similar routes of transmission, co-infection with HBV and HIV is common 
(Soriano, et al., 2007). In addition, HIV coinfection is known to impact the course of HBV 
infection. HIV-HBV coinfection has a potential to increase the risk of perinatal HBV 
transmission and is linked to a more aggressive disease course of chronic hepatitis B (Puoti et 
al., 2006, Hoffmann and Thio, 2007, Sangare et al., 2009, Kourtis et al., 2012). Chronicity of 
HBV is dependent on the age of acquisition. A person coinfected with HBV-HIV and not on 
treatment are likely to become chronically infected. Co-acquisition of HBV and HIV in 
adulthood may results in an increased probability of progressing to fulminant liver failure. This 
is indicated by HBV replicating to high levels, resulting in of cirrhosis and HBV-induced 
hepatocellular carcinoma (Thio et al., 2002, Levy and Grant, 2006, Puoti et al., 2006). In areas 
with low HIV prevalence, chronic HBV prevalence is ten times higher in people living with 
HIV (Thio et al., 2002, Soriano et al., 2005, Levy and Grant, 2006).  
 
HBV-HIV co-infected patients have also been observed to have a higher prevalence of HBeAg, 
which is the indicator of infectivity, higher HBV DNA titers and more occult HBV infections 
(Gilson et al., 1997, Colin et al., 1999, Puoti et al., 2006). It has also been reported that co-
infected patients are more unlikely to produce anti-HBs (HBsAb) after HBV vaccination (Shire 
et al., 2006, Kim et al., 2009). In HBV-HIV coinfection patients, there is a 3- fold increase in 
observing liver related mortality compared to patients who were mono- infected with either 
disease (Bonacini et al., 2004, Weber et al., 2006). However, there is no evidence that active 
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HBV disease may create an immune active environment and enhance HIV disease progression 
(Soriano et al., 2018). High prevalence of HIV and HBV co-infection also has implications for 
treatment (Rouet et al., 2004) and could affect the choice of treatment as some of the 
antiretroviral agents are active against both HIV and HBV.  
 
2.6.2 HBV-HIV co-infection prevalence  
Approximately 3.3 million (10%) people infected with HIV are also co-infected with HBV 
globally and 2.6 million of these reside in sub-Saharan Africa. West and Southern Africa are 
the most affected African regions, with up to 36% of chronic HIV-HBV coinfection in 2014 
(Matthews et al., 2014)). Many African countries report high HBV-HIV co-infection rates with 
prevalence ranging from 4.0% to 28.0% (Figure 2.4.) (Barth et al., 2010). Nigeria has the 
highest prevalence of HIV-HBV coinfection (ranging between 10% and 70%) and Zambia has 
the lowest prevalence (7%) compared to other African countries (Barth et al., 2010). 
 
In South Africa, HIV and HBV co-infection rates range from 0.4% to 22.9% (Lukhwareni, et 
al., 2009; Barth, et al., 2011), with 3.1% found in pregnant women in KwaZulu Natal, 4.8% in 
urban cohorts and 22.9% in a cohort in Limpopo (Firnhaber, 2008, Firnhaber et al., 2009, 
Lukhwareni et al., 2009, Thumbiran et al., 2014). Another study of 100 consecutive AIDS 
patients in Johannesburg, South Africa, showed that 6% of patients were co-infected with 
HBV, and 35% had markers of previous exposure to HBV (Lodenyo, Schoub, Ally, Kairu, & 
Segal, 2000). 
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Figure 2.4. HBV-HIV co-infection prevalence in selected African countries (Barth et al., 
2010) 
2.7 Treatment of HBV and HIV infections 
In most instances acute hepatitis infection is self-resolving but if the infection worsens or 
chronic hepatitis infection is suspected, treatment is required to reduce the risk of liver cirrhosis 
and liver cancer development. Therapies like tenofovir can also be used for the treatment of 
HBV infection (Lok and McMahon, 2007) as first line therapy. Treatment of chronic hepatitis 
mono-infection depends on the phase of the chronic infection or if the individual requires 
immunosuppressive therapy. The HBV infection can be successfully treated with lamivudine 
which acts on the reverse transcriptase path of the virus replication (Gitlin, 1997). Lamivudine 
should not be used except in certain clinical situations such as fulminant liver failure as it has 
low genetic barrier to resistance 
 
In South Africa, current ART guidelines recommend that HIV-infected individuals being 
initiated on ART treatment, should be tested for HBV as antivirals can lead to potentially life-
threatening flares of hepatitis B if HIV treatment is stopped. In addition, patients coinfected 
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with HIV-HBV should be treated with antiretroviral therapy (ART) that is active against both 
HBV and HIV. Emtricitabine (FTC), lamivudine (3TC), tenofovir disoproxil fumarate (TDF) 
and tenofovir alafenamide fumarate (TAF) are all active against HBV and HIV. Due to its 
superior resistance profile, a first-line ART regimen that contains tenofovir is recommended 
for treating HIV-HBV co-infection individuals (Hamers et al., 2013) combined with 
emtricitabine and lamivudine, which have excellent safety profiles. A fixed-dose combination 
(FDC) antiretroviral (ARV) regimen consisting of tenofovir (TDF), emtricitabine (FTC) and 
efavirenz (EFV) is currently recommended for all HIV-infected individuals in South Africa 
(Department of Health, 2013). 
 
2.8 Hepatitis immunization programme in South Africa 
With the use of the HBV vaccine in most countries, there is substantial evidence of the impact 
on the reduction of the HBV prevalence globally. Taiwan, the first country to initiate a HBV 
vaccine programme in 1984, reduced HBsAg prevalence to 0.7% in children younger than 15 
years by 1999 (Ni et al., 2001, Hou et al., 2005). In 1995, South Africa became one of the first 
countries in Africa to introduce the HBV vaccine as part of the National Expanded Programme 
of Immunisation (EPI) (Tsebe et al., 2001). The hexavalent vaccine is given to infants at 6, 10 
and 14 weeks of age and again at 18 months (Tsebe et al., 2001) and the dose is according to 
age. The monovalent vaccine given at birth or as part of the adult catch up program is a 
genetically engineered recombinant HB vaccine that stimulates the immune response to 
produce antibodies against the disease (Department of Health, 2009). Numerous studies have 
shown that the HBV vaccine is highly immunogenic and effective (Burnett et al., 2012). Since 
its introduction, it has resulted in robust immunity against HBV among South Africans aged 1-
25 years old (Burnett et al., 2012). The HBV vaccine has led to an increase in anti-HBs 
(HBsAb) from 13% to 57% and steady decline in HBsAg carriage from 4.2% to 1.4% in the 
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post-vaccine era (Amponsah-Dacosta et al., 2014). However, there is no catch-up vaccination 
programme for older children and adults to ensure complete vaccination coverage (Tsebe et al., 
2001). Between 1995 and 1999, 31.0% of mothers of 8 to 72 month–old children in South 
Africa had evidence of current or past exposure to HBV (Tsebe et al., 2001). A recent study 
showed a 10%  HBV prevalence in infants attending one of the KwaZulu Natal hospitals 
(Mdlalose et al., 2016). It was also shown that only 10.0% of black African babies were 
receiving the vaccine (Kew, 2008b). There could be reasons for the low coverage amongst 
which are difficulty in accessing the vaccine and dealing with low supply chain issues, financial 
constraints of individuals preventing accessing the vaccine, other illnesses including HIV, 
AIDS and TB, political issues, other communicable diseases being prioritized by government, 
the lack of understanding as to the extent of the HBV epidemic in South Africa (Kew, 2008b).  
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Key Messages 
• Hepatitis B virus (HBV) infection in some populations has not been well described 
and remains an important cause of morbidity and mortality.  
• Surveillance for hepatitis B virus surface antigen (HBsAg), a marker of HBV 
infection, is an important measure of the burden of infection. 
• Hepatitis B virus nucleocapsid antigen (HBeAg), is an important marker of acute 
infection and identifies individuals who have high levels of virus and are at high risk 
of transmitting the HBV; therefore, an important measure of sustained transmission.  
• Scale up of HBV prevention programmes to include immunisation and treatment is 
an important missed opportunity to reduce the spread of HBV  
 
Research in context 
Evidence before this study 
Despite the availability of a highly effective vaccine in South Africa, hepatitis B virus (HBV) 
infection is an important cause of morbidity and mortality. Apart from studies on 
seroprevalence of hepatitis B surface antigen (HBsAg), a marker of HBV infection, among 
pregnant women attending public sector facilities, there are no large scale population-based 
studies that provide reliable estimates on the HBV burden in the general population.  
Added value of this study 
This study determined the seroprevalence of HBV infection in the general population 
HBsAg, HBeAg and anti-HBe markers were measured among 9791 men and women 15-49 
years old in rural and periurban areas of the uMgungundlovu district in KwaZulu-Natal, 
South Africa. Thus, we provide critical data on the population seroprevalence of HBV 
infection to guide the strategic prioritisation of HBV immunisation and treatment 
programmes. 
Implications of all the available evidence 
The overall seroprevalence of HBsAg was 4.0%; 4.8% in men and 3.2% in women.  
Furthermore, an estimated 35.1% of HBsAg positive participants were HBeAg positive; 
36.9% of men and 32.6% of women. These findings highlight an important missed 
opportunity to establish HBV surveillance, testing for linkage to immunisation or treatment 
programmes for men and women in this community to achieve the World Health 
Organization’s (WHO) goal of eliminating viral hepatitis as a major public health threat by 
year 2030. 
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Abstract 
Background: In South Africa, hepatitis B virus (HBV) infection remains a major cause of 
morbidity and mortality, however, little is known about the prevalence and distribution of 
HBV in some regions and populations.  
 
Methods: This secondary analysis is based on 9791 participants (15-49 years old) enrolled in 
the HIV incidence Provincial Surveillance System (HIPSS); a population-based household 
study undertaken from June 2014 to June 2015 in the Vulindlela (rural) and Greater Edendale 
(periurban) areas of the uMgungundlovu district, KwaZulu-Natal (KZN), South Africa. 
Interviewer administered questionnaires were completed to obtain demographic, psycho-
social, behavioural and clinical information. Peripheral blood samples were collected and sera 
were tested for hepatitis B surface antigen (HBsAg) and all samples testing positive were 
further tested for hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe). The 
estimated weighted seroprevalence of HBV markers was calculated and the association of 
HBsAg with sociodemographic and behavioural factors measured. 
 
Results: The overall HBsAg prevalence was 4.0% (95% confidence interval (CI) 3.4-4.5); 
4.8% (95% CI 3.8-5.8) in men and 3.2% (95% CI 2.5-3.9) in women, P=0.01. Among HBsAg 
positive participants, 35.2% (95% CI 29.2-41.2) were HBeAg positive and 66.3% (95% CI 
60.1-72.4) were anti-HBe positive. Among men 15-19 years old HBeAg seroprevalence was 
92.2% (95% CI 75.8-100) compared to 4.4% (95% CI 0-13.7) in women in the same age group; 
P<0.01. HBsAg prevalence was 6.4% (95% CI 5.3-7.5) among HIV positive participants 
compared to 2.6% (95% CI 1.9-3.2) among HIV negative participants, (P<0.01) and was higher 
among HIV positive men 8.7% (95% CI 6.3-11.2) compared to HIV positive women 5.0% 
(95% CI 3.8-6.2), P<0.01. 
 
Conclusion: HBV infection, particularly among HIV positive men remains an important public 
health problem in rural and periurban communities in KwaZulu-Natal, South Africa. The 
prevalence of HBsAg and HBeAg highlight the importance of surveillance and an important 
missed opportunity for the scale up of programmes to achieve the goal of controlling HBV for 
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Introduction 
Hepatitis B virus (HBV) infection is a common cause of viral hepatitis and affects more than 
257 million people worldwide. Almost eight percent of this global burden is in sub-Saharan 
Africa, with over 80 000 new infections occurring each year (World Health Organisation., 
2017). In South Africa, HBV infections accounts for an estimated 3.5 million infected 
individuals (Schweitzer et al., 2015).   HBV remains endemic in the region. Viral hepatitis from 
HBV infections is a potentially life-threathening liver infection resulting in acute hepatitis and 
chronic liver disease, leading to complications of cirrhosis and hepatocellular carcinoma; 
contributing to high rates of morbidity and mortality (World Health Organisation., 2017).  
 
The transmission of HBV is known to occur through multiple routes. The most common being 
mother-to-child at birth or through exposure to infected blood (Kiire, 1996). Other routes of 
transmission include sexual transmission, percutaneous or mucosal exposure to infected blood 
and various body fluids. Transmission can also occur through saliva, menstrual, vaginal, and 
seminal fluids, and iatrogenic spread through re-use of contaminated needles. Equipment in 
health-care settings, or among persons who inject drugs and use of razors or similar objects 
during ritual scarification may be routes of transmission (Kew, 1996a, Mphahlele et al., 2002, 
Heiberg et al., 2010). 
 
South Africa has been in the forefront of introducing new vaccines and as early as 1995, the 
country introduced the HBV vaccine as part of the Expanded Programme on Immunisation. By 
2015 South Africa had become the first African country to phase out the pentavalent vaccine 
and replaced it with the more baby-friendly hexavalent vaccine (Dlamini and Maja, 2016). 
Despite the introduction of these vaccines, there are no nation-wide surveillance programmes 
that measure and monitor trends in HBV (Mayaphi et al., 2012). Thus, data on burden of HBV 
including clinical manifestation of advancing disease are limited and are based on cohort 
studies undertaken more than a decade ago. Prior to the immunisation programme, 
approximately 6.5 million South Africans were HBV carriers, with prevalence being highest 
among school-going children, people residing in rural areas and among sexually active 
individuals (Schneider et al., 1977, Botha et al., 1984, Dibisceglie et al., 1986, Burnett et al., 
2005). The prevalence of HBV infection in rural areas was estimated to be between 5% and 
16% among men and 4% and 12% among women, while in urban areas, rates were between 
8% and 9% among men and 3% and 4% among women (Kew et al., 1976, Vos et al., 1980, 
Prozesky et al., 1983, Kew et al., 1987, Abdool Karim et al., 1988, Dusheiko et al., 1989). 
Samsunder – Seroprevalence of HBV 
28 
Currently, there are an estimated 3 to 4 million hepatitis B carriers in South Africa (Kew, 
2008a).  
 
Given that the World Health Organisation strategy is to eliminate HBV as a public health threat 
by the year 2030, (Perz et al., 2006, World Health Organisation., 2016, World Health 
Organisation., 2017) it is important to establish what the seroprevalence is through 
surveillance. The purpose of this study was to assess the HBV seroprevalence as part of a 
household survey in rural and periurban areas in KwaZulu-Natal, South Africa. 
 
Materials and Method 
Study design, setting and population 
This secondary analysis is based on testing of samples from participants enrolled in the HIV 
incidence Provincial Surveillance System (HIPSS). The HIPSS study design, source 
population, recruitment and enrollment procedures have been previously described (Kharsany 
et al., 2015, Kharsany et al., 2018). Briefly, HIPSS was a population-based household study 
conducted in the Vulindlela (rural) and the Greater Edendale (periurban) areas in the 
uMgungundlovu district of KwaZulu-Natal, South Africa. The study used a multi-stage cluster 
sampling method to randomly select enumeration areas, households, and individuals, resulting 
in a total of 9812 men and women (15-49 years old) enrolled between June 2014 and June 
2015. All enrolled participants provided written informed consent and/or parental consent/child 
assent for those participants below the age of 18 years for study participation and for long-term 
storage of clinical samples for future testing; completed interviewer administered 
questionnaires; had peripheral blood samples collected and allocated a unique identification 
number with a linking number to link the household, participants’ questionnaire and laboratory 
data. 
 
The Biomedical Research Ethics Committee (BREC) of the University of KwaZulu-Natal 
reviewed and approved the HBV seroprevalence protocol (BE057/17), the HIPSS study 
protocol, informed consent and questionnaire forms (BF269/13). The Centers for Disease 
Control and Prevention from the United States of America and the Provincial Department of 
Health (KwaZulu- Natal (HRKM 08/14) approved the HIPSS study protocol. All participants 
were referred to their local primary health care clinics to access their study related laboratory 
test results and for individualised HIV testing services. Prior to any interaction with household 
members and participants, community engagement processes were established with key 
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community stakeholders including health-service providers and traditional leadership and key 
members from community structures. 
 
Laboratory tests 
Peripheral blood samples were shipped to the laboratory within six hours of collection. Of the 
9812 participants enrolled in HIPSS, blood samples from 21 (0.2%) were insufficient for any 
HBV testing and were excluded  
 
Testing for HBV  
For the detection of markers of HBV infection, testing was performed using the automated 
ADVIA Centaur System (Siemens, Tarry Town, USA) which utilizes magnetic particle 
separation technology with direct chemiluminescence. The HBV assay panel included the 
qualitative detection of HBsAg, HBeAg and anti-HBe. HBsAg positive samples were further 
tested for HBeAg and anti-HBe. All results were reported as positive or negative. The 
diagnostic specificity are reported to be 99.4% for the HBsAg assay, 99.5% for the HBeAg 
assay and 98.2% for the anti-HBe assay (van Helden et al., 2004, van Helden et al., 2008). 
 
Interpretation of HBV test results 
In this study we defined HBV status (North Carolina Hepatitis B Public Health Program 
Manual., 2012) as: 
HBsAg positive: the presence of HBsAg in serum indicates that the individual has a current 
infection.  
HBeAg positive: the presence of HBV nucleocapsid gene (HBeAg) in serum indicates active 
viral replication in individuals with acute or recently acquired infection, have high levels of 
viraemia and more likely to transmit the virus.  
Anti-HBe positive: the presence of antibodies to HBV nucleocapsid gene (HBeAb) indicates 
that the individual is recovering as a result of an immune system response to the HBeAg and 
has a reduced level of infectivity. 
HBV and HIV positive: this indicates that the individual is co-infected with HBV (HBsAg 
positive) and HIV-1 infection. 
 
Testing for HIV  
HIV testing was performed using the 4th generation HIV enzyme Biomeriuex Vironostika 
Uniform 11 Antigen/Antibody Microelisa system (BioMerieux, Marcy I ‘Etoile, France) and 
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HIV 1/2 Combi Roche Elecys (Roche Diagnostics, Penzberg, Germany). Samples testing 
indeterminate for HIV were further tested using ADVIA Centaur HIV Antigen/Antibody 
Combo (CHIV) Assay (Siemens, Tarry Town, USA). 
 
Statistical Analysis 
Participants laboratory and questionnaire data were merged using a unique linking number. All 
analyses were performed using SAS 9.4 (SAS Institute Inc. Cary, NC) survey procedures. 
Sampling weights were calculated taking into account the probabilities of selecting the 
enumeration area, the household in the enumeration area, and the individual in the household, 
weighted for sampling, participation bias, and non-response; and rescaled to the size of the 
population in the survey area with the StatsSA 2011 Census population (Kharsany et al., 2018). 
Descriptive statistics with counts and population-weighted percentages with 95% CIs are 
presented for key demographic, psychosocial and behavioural factors. Taylor series 
linearization method was used to estimate standard errors of estimates, from which Wald 
confidence limits were derived. The Rao-Scott Chi-Square test is used to test for the association 
between prevalence and sociodemographic, behavioural and clinical characteristics. 
 
Results 
Demographic characteristics of the study participants 
Among the 9791 participants tested for HBV infection, the median age of the 3541 (36.2%) 
men was 27 years [Interquartile range (IQR) 21-35 years] and of the 6250 (63.8%) women was 
28 years (IQR 21-37). The majority of participants were single (92.1% of men and 85.8% of 
women), reported having 1 to 5 lifetime number of sexual partners (39.0% men and 51.3% 
women), and lived in rural areas (57.3% men and 58.7% women).  In addition, prevalence of 
HIV (28.0% men and 44.0% women) and sexually transmitted infections (STIs) (52.3% men 
and 78.3% women) was high. Over a third of participants had incomplete secondary education 
(38.1% of men and 41.3% of women) and earned a monthly income of between South African 
Rand (ZAR) 501-ZAR2500 (44.5% men and 46.3% women). Overall, consistent condom use 
during sex in the last 12 months was low (Table 3.1). 
 
Seroprevalence of HBsAg 
Among the 9791 participants, 361 were HBsAg positive with an overall weighted 
seroprevalence of 4.0% (95% confidence interval (CI) 3.4-4.5) (Table 3.2). Seroprevalence in 
women was 3.2% (95% CI 2.5-3.9) and was higher in men at 4.8% (95% CI 3.8-5.8); P=0.01. 
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Seroprevalence varied with age among men (P <0.01) and women (P <0.01). Seroprevalence 
was 1.1% (95% CI 0-2.3) among men in the 15-19 year old age group and steadily increased 
to reach a peak of 9.6 % (95% CI 5.0-14.1) in the 40-44 year old age group. In contrast, among 
women seroprevalence was consistently lower in each of the age groups and was 0.9% (95% 
CI 0-1.8) among women 15-19 years old and peaked at 6.0% (95% CI 3.1-8.9) in the 30-34 
year old age group. Seroprevalence increased with an increasing number of lifetime sex 
partners in women (P <0.01), with HIV positive status among men (P <0.01) and women (P 
<0.01) and with positive STIs (other than HIV) among men (P<0.01). There were no 
differences in seroprevalence among rural and periurban men (P =0.69) and rural and periurban 
women (P =0.92). 
 
Seroprevalence of HBeAg  
Of the 361 HBsAg positive samples, 357 had sufficient sample for HBeAg testing. Of these, 
133 were HBeAg positive with an overall weighted seroprevalence of 35.2% (95% CI 29.2-
41.2) (Table 3.3). HBeAg seroprevalence in men was 36.9% (95% CI 27.5-46.2) and in women 
was 32.8% (95% CI 32.3-41.9); P=0.58. Among men 15-19 years old HBeAg seroprevalence 
was 92.2% (95% CI 75.8-100) compared to 4.4% (95% CI 0-13.7) in women in the same age 
group; P <0.01. Similarly, HBeAg seroprevalence was higher among men aged 40-44 years 
old 55.5% (95% CI 30.6-80.4) compared to 27.7% (95% CI 10.4-45.0) in women in the same 
group. However, seroprevalence of HBeAg among men and women across the other age groups 
was similar. There were no differences in seroprevalence of HBeAg among men in rural 34.0% 
(95% CI 24.0-44.0) and periurban areas 38.9% (95% CI 24.6-53.2), P = 0.58, or women in 
rural 36.7% (95% CI 26.9-45.9) and periurban areas 30.0% (95% CI 16.1-43.9), P=0.43. 
 
Seroprevalence of anti-HBe  
Of the 361 HBsAg positive samples, 356 had sufficient sample for anti-HBe testing. Of these, 
237 samples were positive for anti-HBe with an overall weighted seroprevalence of 66.3% 
(95% CI 60.1-72.4) (Table 3.3). Seroprevalence in men was 64.5% (95% CI 54.7-74.3) and 
was similar in women at 68.8% (95% CI 59.3-78.3), P = 0.51. Anti-HBe seroprevalence was 
high among men and women across most age groups. More women than men in the age group 
15-19 years old were anti-HBe positive 81.0% (95% CI 45.5-100) vs 7.8% (95% CI 0-24.2), P 
<0.01. Similarly, among women in the age group 40-44 years old seroprevalence was 76.8% 
(95% CI 60.9-92.7) compared to 47.1% (95% CI 21.6-72.6) in men in the same age group, 
P=0.03. There were no differences in seroprevalence of anti-HBe among men in rural (61.4%, 
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95% CI 46.7-76.1) and periurban areas (68.9%, 95% CI 57.4-80.3), P=0.43 and among women 
in rural (69.3%, 95% CI 54.4-84.2) and periurban areas (68.1%, 95% CI 58.6-77.6), P=0.89. 
 
HBV-HIV co-infection 
Of the 3955 HIV positive participants, 229 were also infected with HBV, of which 91were men 
and 138 were women. HBV seroprevalence was 6.4% (95% CI 5.3-7.5) among HIV positive 
participants compared to 2.6% (95% CI 1.9-3.2) among HIV negative (n=5836) participants; 
P<0.01. Among HIV positive men, seroprevalence of HBsAg was 8.8% (95% CI 6.3-11.2) 
compared to 3.3% (95% CI 2.3-4.3) among HIV negative men; P<0.01. Among HIV positive 
women, seroprevalence of HBsAg was 5.1% (95% CI 3.8-6.3) compared to 1.7% (95% CI 1-
2.3) among HIV negative women; P<0.01. Differences in HBsAg prevalence among HIV 
positive and negative individuals was greatest in age groups 20-24 and 25-29. Overall, 
seroprevalence of HBsAg was higher among HIV positive participants in the 20-24 and 25-29 
years old age groups, P<0.01 (Figure 3.1). Among HIV positive men in the age group 20-24 
years old HBsAg seroprevalence was 11% (95% CI 2.8-19.2) compared to 2.7 % (95% CI 1.0-
4.5) among HIV negative men in the same age group; P<0.01. Among HIV positive women in 
the age group 20-24 years old, HBsAg seroprevalence was 6.2% (95% CI 2.8-9.7) compared 
to 1.0% (95% CI 0.3-1.6) among HIV negative women in the same age group; P<0.01. 
Similarly, among HIV positive women in the 25-29 year old age group HBsAg seroprevalence 
was 6.4% (95% CI 3.3-9.5) compared to 1.3% (95% CI 0.4-2.1) among HIV negative women 
in the same age group; P<0.01. 
 
Discussion  
In this population-based study in the rural and periurban areas of the uMgungundlovu district 
of KwaZulu-Natal, South Africa, the overall HBsAg seroprevalence among men and women 
in the age group 15-49 years old was 4.0%, with a seroprevalence of 4.8% in men and 3.2% in 
women. While lower than the HBsAg seroprevalence of 6.1% reported for sub-Saharan Africa, 
(Spearman et al., 2017) and between 5.3% and 9.7% in recent cohort studies among pregnant 
women (Thumbiran et al., 2014, Matthews et al., 2015), this still represents a substantial HBV 
burden. South Africa has been reported to be at the forefront on the implementation of the 
Expanded Programme on Immunisation which includes HBV immunisation, (Dlamini and 
Maja, 2016) however, the prevalence of HBV infection remains moderate to high, especially 
in the age group 15-19 years old as this age group should have benefitted from the 
immunisation programme. In the absence of an active HBV surveillance programme it is 
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unlikely that HBV immunisation and treatment programmes are easily accessible and reach 
individuals where the needs are the greatest. These findings emphasise that HBV remains an 
important public health problem and all efforts to achieve the WHO targets for the elimination 
of viral hepatitis are urgently needed (World Health Organisation., 2016). WHO in 2016 set 
ambitious targets of a 90% reduction in new cases of HBV infection and an associated 65% 
decline in HBV related mortality to be achieved by the year 2030. These measures rely on 80% 
of treatment eligible individuals with chronic HBV infection to be on treatment (World Health 
Organisation., 2016).  
Whilst vertical transmission of HBV is the commonest route of transmission, the age specific 
HBV data highlighted several important findings. Firstly, men had higher seroprevalence 
compared to women in every age group. Secondly, the data showed a bimodal distribution of 
seroprevalence of HBsAg among men in the 30-34 and 40-44 year old age groups whilst in 
women, peak seroprevalence occurred in the 30-34 year old age group. These findings show 
that the peak prevalence occurred among men and women in the age groups that are likely to 
sustain the transmission of HBV. Thirdly, overall estimates are useful to understand the burden 
of HBV infection in the general population, however, disaggregation by sex and age provides 
a more precise understanding of the age group that might be affected and allows for 
prioritisation and targeted interventions to further reduce this burden. Several studies have 
shown urban-rural differences with the highest prevalence of HBsAg infection found in men 
residing in rural areas, placing a greater burden on rural health care services (Vos et al., 1980, 
Abdool Karim et al., 1988, Abdool Karim et al., 1991, Lodenyo et al., 2000, Hoffmann et al., 
2008, Firnhaber et al., 2008, Di Bisceglie et al., 2010). However, this study found no 
differences in the seroprevalence of HBsAg among men and women, irrespective of their area 
of residence being rural or periurban. It is possible that extensive in- and out- migration in the 
study community and cultural practices of scarification (Abdool Karim et al., 1988) may not 
clearly delineate urban-rural differences. 
This study found that at least a third of men (36.9%) and women (32.6%) were HBeAg positive 
and therefore more likely to be infectious. These prevalence values are higher than the 16.7% 
-30.0% observed in cohorts of pregnant women in South Africa (Thumbiran et al., 2014). 
Whilst men in the 15 to 19 year age group and women in the 20 to 24 year old age groups had 
low seroprevalence of HBsAg, more than 90% of these men and about 60% of these women 
were positive for HBeAg, suggesting that these individuals were in the acute stage of infection 
and have a high HBV viral load (Spearman et al., 2017) and therefore highly infectious. The 
high prevalence of HBeAg among both men and women highlights the sustained transmission 
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in this community. Reaching out to men and women at high risk of transmitting HBV with 
messaging on immunisation and treatment options could further guide and scale-up targeted 
programming and strategies to reduce the further spread of HBV and the opportunity for a 
catch-up immunisation programme targeting young boys. 
An overall seroprevalence of HBsAg of 6.4% among HIV positive individuals was observed, 
with a higher seroprevalence amongst HIV-positive men (8.8%) compared to HIV-positive 
women (5.1%). Since, HBV-HIV share similar routes of transmission, co-infections are likely 
to be common and are reported to range from 5% to 30% (Abdool Karim et al., 1991). Although 
co-infections were low at 0.8% in the 15 to 19 year old age group, co-infections were high in 
all other age groups, ranging from 6.4% to 11.9%. Identifying co-infections is important as 
HBV infections are associated with an increased risk of liver disease. ART use in HIV positive 
individuals may be compromised by drug associated hepatotoxicity leading to the use of 
complex regimens (Di Bisceglie et al., 2010). In addition, our study showed that among 
women, HBV-HIV co-infections were above six percent in age groups that women are in their 
reproductive years and are already disproportionately burdened with HIV, (Kharsany et al., 
2015). This could potentially increase the risk of HBV and HIV transmission. Expanding 
treatment for HBV and HIV positive individuals could limit onwards transmission of both 
infections. Even initiating ART in the absence of HBV, reduces the risk of new HBV cases and 
reduces the risk of mother to child transmission of HBV (Di Bisceglie et al., 2010). Therefore, 
public sector ART and antenatal care programmes are missed opportunities to screen for HBV 
at the time of testing for HIV and when initiating ART. These individuals would benefit from 
immunisation if HBV negative or if positive to receive treatment to prevent the onward and 
mother-to-child transmission of HBV (Cui et al., 2018).  
This study has several strengths and limitations. A key strength was our measurement of HBV 
seroprevalence in a large randomly selected study sample from a population-based household 
survey. Furthermore, the sex and age disaggregated data provides a nuanced understanding of 
the segments of population that might be affected, though our sample was not representative 
of all age groups. Our results are from cross sectional data and are limited to the Greater 
Edendale and Vulindela areas of KwaZulu-Natal, South Africa and not necessarily 
generalizable to other settings. It is important to note that this study was not able to fully assess 
the impact of HBV immunisation programme on seroprevalence of HBV markers, as the 
benefit would be in the<15 year old age groups rather than those included in our sample (Tsebe 
et al., 2001). Our testing strategy did not include the full HBV testing panel to comprehensively 
classify individuals; for example, we did not test for occult HBV infection, HBV viral load and 
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for hepatitis B core antibody (anti-HBc) or hepatitis B surface antibody (anti-HBs) to determine 
recovery and/or immunity from HBV infection. Lastly, prevalence of HBeAg may be 
unreliable due to small sample sizes in the age specific strata. Nevertheless, the HBeAg data 
provide a reasonable signal of the sustained HBV transmission in this community. 
 
Conclusion 
Our findings show that HBV infection is an important public health problem. Men across all 
age groups and women in the age group 20 to 24 and 25 to 29 years old had the highest 
seroprevalence of HBsAg. Furthermore, more than a third of these men and women were 
HBeAg positive underscoring the risk of sustained onward HBV transmission in this 
community. Ensuring that HIV positive individuals with HBV infection are initiated on 
treatment to reduce viral loads of both HIV and HBV is essential. These findings highlight the 
importance of surveillance and an important missed opportunity for the scale up of programmes 
to achieve the overall goal of controlling HBV for public health benefit.  
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Table 3.1: Sociodemographic, behavioural and clinical characteristics of participants 15-
49 years, enrolled between June 2014 and June 2015 in rural and periurban areas of 
KwaZulu-Natal, South Africa 
 Men  Women  
 (n=3541) (n=6250) 
Median (IQR) age 27 (21-35) 28 (21-37) 
Age groups in years, number in sample, (weighted %) 
15-19 657(19.6) 956 (18.1) 
20-24 813 (20.9) 1262 (19.5) 
25-29 602 (18.3) 1085 (17.9) 
30-34 459 (13.9) 831 (13.7) 
35-39 404 (12.3) 757 (12.2) 
40-44 319 (8.6) 660 (9.6) 
45-49 287 (6.5) 699 (8.9) 
Relationship status, number in samples, (weighted %)    
Single (includes divorced, separated, widowed) 3300 (92.1) 5288 (85.8) 
Married 180 (5.9) 681 (11.7) 
Living with someone 61 (2.0) 175 (2.5) 
Education, number in samples, (weighted %)b  
Incomplete secondary or less  
Complete secondary 
1929 (56.5) 3306 (53.4) 
1403 (38.1) 2597 (41.3) 
Tertiary  207 (5.4) 344 (5.3) 
Income per household per month,  number in samples, (weighted %)c 
No income 523 (13.2) 764 (10.4) 
<ZAR500 293 (6.2) 610 (7.3) 
ZAR501-2500 1434 (44.5) 2713 (46.3) 
ZAR2501-6000 914 (35.5) 1558 (34.6) 
>ZAR6000 30 (0.9) 70 (1.5) 
Geographic location,  number in samples, (weighted %) 
Urban  2296 (42.8) 4047 (41.3) 
Rural 1245 (57.3) 2203 (58.7) 
Lifetime # sexual partners,  number in samples, (weighted %)d  
0 partners 691 (21.2) 816 (15.6) 
1 partner 420 (13.8) 1543 (28.9) 
1-5 partners 1196 (39.0) 2848 (51.3) 
>5 partners 758 (26.1) 280 (4.3) 
HIV status,  number in samples, (weighted %) 
Negative 2531 (72.1) 3305 (56.0) 
Positive 1010 (28.0) 2945 (44.0) 
Self-reported to be on ART (HIV positive only), number in samples, (weighted %)  
No 669 (63.1) 1695 (54.3)  
Yes 341 (36.9) 1250 (45.7) 
 STIa present, number in samples, (weighted %) 
No 1689 (47.7) 1354 (21.7) 
Yes 1852 (52.3) 4896 (78.3) 
Condom use during sex in the last 12 months for those sexually active in the last 12 months , number in samples, 
(weighted % )  
Always  593 (25.2) 992 (22.8) 
Sometimes 1290 (54.9) 2317 (53.4) 
Never  468 (19.9) 1032 (23.8) 
% = Population weighted percentage; IQR= Interquartile range, ZAR= South African Rand; a =any laboratory diagnosis 
of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and/or Mycoplasma genitalium DNA from self-
collected swabs (women) and first-pass urine (men) samples and antibodies to herpes simplex virus type 2 and Treponema 
pallidum (syphilis). (Kharsany et al., 2015)   b=2 men and 3 women were missing education data; c=347 men and 535 
women were missing income data; d=476 men and 763 women did not provide their number of lifetime partners 
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Table 3.2: Seroprevalence of HBsAg and association with sociodemographic, behavioural 
and clinical characteristics of 9791 participants (15-49 years), enrolled between June 2014 
and June 2015 in rural and periurban KwaZulu-Natal, South Africa 
  
Variable 








Weighted %  
(95% CI) 
Seroprevalence of HBsAg   
Overall 165/3541 4.8 (3.8-5.8) 196/6250 3.2  (2.5-3.9) 
By Age group in years      
15-19 7/657 1.1 (0-2.3) 8/956 0.9 (0-1.8) 
20-24 26/813 3.6 (1.7-5.4) 32/1262 2.7 (1.5-3.8) 
25-29 30/602 4.5 (2.4-6.6) 39/1085 3.8 (2.2-5.4) 
30-34 40/459 7.8 (4.5-11) 40/831 6.0 (3.1-9) 
35-39 23/404 5.6 (3.1-8.1) 27/757 2.9 (1.4-4.5) 
40-44 24/319 9.6 (5-14.1) 26/660 4.1 (1.9-6.3) 
45-49 15/287 6.6 (2.3-10.8) 24/699 2.5 (1.3-3.8) 
  P value <0.01c  P value <0.01 c 
Relationship status  






Married 12/180 5.7 (2.3-9.2) 16/681 2.9 (1.1-4.7) 
Living with someone 3/61 8.6 (0-20.3) 7/175 4.3 (0.6-8.1) 






  P value= 0.52 c  P value= 0.79 c 
Educationd             
Incomplete secondary or less 96/1929 5.3 (4-6.7) 116/3306 3.3 (2.6-4.0) 
Complete secondary 60/1403 4.1 (2.6-5.6) 75/2597 3.3 (2.1-4.5) 
Tertiary  9/207 4.3 (0.4-8.3) 5/344 1 (0-2.1) 
  P value=0.49 c  P value=0.16 c 
Income per household per month a,e  
No income 28/523 5.5 (2.9-8.1) 23/764 3 (1.2-4.8) 
<ZAR500 19/293 5.5 (2.6-8.3) 24/610 4.5 (2.2-6.8) 
ZAR501-2500 66/1434 4.9 (3.2-6.5) 96/2713 3.3 (2.5-4.1) 
ZAR2501-6000 37/914 4.2 (2.6-5.9) 39/1558 2.8 (1.3-4.3) 
>ZAR6000 1/30 5.4 (0-15.9) 3/70 7 (0-15.5) 
  P value=0.91 c  P value=0.48 c 
Geographic location              
Urban  104/2296 4.6 (3.5-5.7) 133/4047 3.2 (2.6-3.8) 
Rural 61/1245 5.0 (3.4-6.5) 63/2203 3.1 (2-4.2) 
  P value=0.69 c  P value=0.92 c 
Lifetime # sexual partnersf            
0 partners 16/691 3.2 (1.1-5.2) 10/816 1.7 (0.3-3.1) 
1 partner 18/420 3.4 (1.6-5.2) 30/1543 1.9 (1-2.9) 
1-5 partners 64/1196 5.2 (3.4-7.1) 103/2848 3.7 (2.7-4.8) 
>5 partners 28/758 4.5 (2.4-6.6) 17/280 6.8 (2.8-10.9) 
  P value=0.41 c  P value<0.01 c 
HIV status             
Negative 74/2531 3.3 (2.3-4.3) 58/3305 1.7 (1.1-2.3) 
Positive 91/1010 8.7 (6.3-11.2) 138/2945 5.0 (3.8-6.2) 
  P value<0.01 c  P value<0.01 c 
Self-reported to be on ART (HIV positive only) 
No 57/669 6.9 (4.5-9.4) 78/1695 4.9 (3.5-6.4) 
Yes 34/341 11.9 (6.8-16.9) 60/1250 5.2 (3.6-6.8) 
  P value=0.05 c  P value=0.78 c 
STIb present             
No 49/1689 2.8 (1.7-3.8) 20/1354 1.9 (0.7-3.1) 
Yes 116/1852 6.7 (5.2-8.3) 176/4896 3.6 (2.8-4.4) 
  P value<0.01 c  P value=0.06 c 
Condom Use in the last 12 months(sexually active in last 12 months only)  
Always  24/593 3.6 (1.9-5.4) 34/992 2.9 (1.5-4.3) 
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Sometimes 66/1290 5.3 (3.5-7.1) 73/2317 3.7 (2.3-5.1) 
Never  27/468 6.1 (3.1-9.0) 35/1032 3.5 (2.1-4.9) 
    P value=0.33c   P value=0.72 c 
%=Population weighted percentages; a=ZAR= South African Rand, ZAR20 ~ GBP1; b=any laboratory diagnosis of 
Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis and/or Mycoplasma genitalium DNA from self-
collected swabs (women) and first-pass urine (men) samples and antibodies to herpes simplex virus type 2 and Treponema 
pallidum (syphilis)(Kharsany et al., 2015); c=p value for the association for variable with HBsAg status; d=2 men and 3 
women were missing education data; e=347 men and 535 women were missing income data; f= 476 men and 763 women 
did not provide their number of lifetime partners; CI= 95% confidence interval.  
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Table 3.3: Seroprevalence of hepatitis B virus makers (HBsAg, HBeAg and anti-HBe) among 
9791 participants (15-49 years), enrolled between June 2014 and June 2015 in rural and 
periurban KwaZulu-Natal, South Africa 
  
Variable 
Men    Women  
n/N 
Weighted %  
(95% CI) 
n/N 
      Weighted %  
(95% CI)        
P valuea 
Seroprevalence of HBsAg    
Overall 165/3541 4.8 (3.8-5.8) 196/6250 3.2  (2.5-3.9)    0.01 
By Age group in years       
15-19 7/657 1.1 (0-2.3) 8/956 0.9 (0-1.8)       0.66 
20-24 26/813 3.6 (1.7-5.4) 32/1262 2.7 (1.5-3.8)    0.40 
25-29 30/602 4.5 (2.4-6.6) 39/1085 3.8 (2.2-5.4)    0.59 
30-34 40/459 7.8 (4.5-11) 40/831 6.0 (3.1-9.0)    0.47 
35-39 23/404 5.6 (3.1-8.1) 27/757 2.9 (1.4-4.5)    0.08 
40-44 24/319 9.6 (5-14.1) 26/660 4.1 (1.9-6.3)    <0.01 
45-49 15/287 6.6 (2.3-10.8) 24/699 2.5 (1.3-3.8)    0.02 
  P value <0.01b  P value <0.01 b  
Seroprevalence of HBeAgc,d    
Overall 65/164 36.9  (27.5-46.2) 68/193 32.8 (23.7-41.9)   0.58 
By Age group in years         
15-19 6/7 92.2  (75.8-100) 1/8 4.4 ( 0-13.7) <0.01 
20-24 10/26 43.3 (18.3-68.4) 17/32 56.7 (32.6-80.8) 0.45 
25-29 11/30 29.8 (11.1-48.5) 12/39 30.2 (9.6-50.7)   0.98 
30-34 15/39 24.8 (9.4-40.1) 14/39 31.0 (11.5-50.5) 0.62 
35-39 7/23 24.7 (6.2-43.1) 8/27 24.6 (7.0-9-42.3)   1.00 
40-44 11/24 55.5 (30.6-80.4) 9/25 27.7 (10.4-45.0) 0.05 
45-49 5/15 23.3 (0.7-45.9) 7/23 34.0 (12.4-55.5) 0.51 
         P value=0.09 b                P value=0.18 b  
Seroprevalence of anti-HBec,e  
Overall  104/163 64.5 (54.7-74.3) 133/193 68.8 (59.3-78.3)  0.51 
By age group in years        
15-19 1/7 7.8 (0-24.2) 7/8 81.0 (45.5-100)   <0.01 
20-24 17/26 64.7 (40.3-89.2) 20/32 65.9 (44.1-87.8)  0.94 
25-29 20/30 69.7 (50.5-88.8) 27/39 62.9 (42.9-82.9)  0.63 
30-34 23/39 70.0 (52-87.9) 25/39 65.4 (40.2-90.6)  0.77 
35-39 18/22 83.0 (66.4-99.5) 20/27 78.5 (60.0-97.1)  0.72 
40-44 15/24 47.1 (21.6-72.6) 17/25 76.8 (60.9-92.7)  0.03 
45-49 10/15 75.2 (51.5-98.8) 17/23 68.3 (46.7-90.0)     0.68 
  P value=0.11b  P value=0.91b  
%=Population weighted percentages; a= p value for the association of HBsAg/HBeAg/HBeAb status and sex by  age 
category;;b=p value for the association of age with HBsAg/HBeAg/ anti-HBe status by sex; c =based on HBsAg 
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